Chemoinformaics analysis of 3,4,5,6-Tetradehydroyohimbine
Molecular Weight | 350.418 | nRot | 1 |
Heavy Atom Molecular Weight | 328.242 | nRig | 26 |
Exact Molecular Weight | 350.163 | nRing | 5 |
Solubility: LogS | -4.041 | nHRing | 3 |
Solubility: LogP | 2.859 | No. of Aliphatic Rings | 4 |
Acid Count | 0 | No. of Aromatic Rings | 1 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 3 |
No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 1 |
nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
nBridge Head | 0 | No. Saturated Carbocycles | 1 |
No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 21 | No. of Saturated Rings | 1 |
No. of Nitrogen atom | 2 | No. of Arom Atom | 13 |
No. of Oxygen atom | 3 | No. of Arom Bond | 14 |
nHA | 5 | APOL | 54.3454 |
nHD | 1 | BPOL | 27.5246 |
QED | 0.686 |
Synth | 4.033 |
Natural Product Likeliness | 0.778 |
NR-PPAR-gamma | 0.407 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Accepted |
Pgp-inh | 0.127 |
Pgp-sub | 0.015 |
HIA | 0.005 |
CACO-2 | -4.821 |
MDCK | 0.0000246 |
BBB | 0.908 |
PPB | 0.843563 |
VDSS | 1.084 |
FU | 0.146435 |
CYP1A2-inh | 0.892 |
CYP1A2-sub | 0.842 |
CYP2c19-inh | 0.518 |
CYP2c19-sub | 0.352 |
CYP2c9-inh | 0.707 |
CYP2c9-sub | 0.293 |
CYP2d6-inh | 0.081 |
CYP2d6-sub | 0.707 |
CYP3a4-inh | 0.926 |
CYP3a4-sub | 0.486 |
CL | 10.388 |
T12 | 0.161 |
hERG | 0.466 |
Ames | 0.798 |
ROA | 0.201 |
SkinSen | 0.13 |
Carcinogencity | 0.64 |
EI | 0.03 |
Respiratory | 0.916 |
NR-Aromatase | 0.453 |
Antiviral | Yes |
Prediction | 0.718801 |